Brief: Rallybio Announces Initiation Of Dosing In RLYB212 Phase 2 Clinical Trial
11/02/2025 13:19
Feb 11 (Reuters) - Rallybio RLYB.O :
* RALLYBIO ANNOUNCES INITIATION OF DOSING IN RLYB212 PHASE 2
CLINICAL TRIAL
* RALLYBIO CORP - PK AND SAFETY DATA EXPECTED IN 2Q AND 3Q
2025
Source text: ID:nBw34KkMla
Further company coverage: RLYB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rallybio
See all newsNASDAQ RESUMED AT 08:48 AM
Brief: Rallybio Corporation And Avenzo Therapeutics Announce Merger Agreement To Advance Next-Generation Oncology Therapies And $215 Million Concurrent Private Placement
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE-Mirum Pharma
U.S. STOCKS ON THE MOVE-Mirum Pharma, eBay, FedEx